MedPath

Efficacy and Safety of Allium Ureteral Stent for Treating Refractory Ureteral Stricture

Not Applicable
Recruiting
Conditions
Hydronephrosis
Ureteral Stent Occlusion
Ureteral Stenosis
Interventions
Device: Allium ureteral stent
Registration Number
NCT05455307
Lead Sponsor
En Chu Kong Hospital
Brief Summary

To conduct a prospective, multi-center study to observe the long-term efficacy and safety of self expanding ureteral stent for treating participants with refractory ureteral stricture.

Detailed Description

The aim of the study is to conduct a prospective, multi-center study to observe the long-term efficacy and safety of self expanding ureteral stent for treating participants with refractory ureteral stricture.

About 200 participants with refractory ureteral stricture will be enrolled in four hospitals. After the allium ureteral stents are placed, renal function, renal echo, images and associated complications will be recorded.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
200
Inclusion Criteria
  • refractory ureteral stricture after at least two times of ureteral dilation
Read More
Exclusion Criteria
  • poor cardiovascular function for anesthesia unwilling to accept the long-term placement of ureteral stent uncontrolled urinary tract infection
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
single armAllium ureteral stentsingle arm without placebo control
Primary Outcome Measures
NameTimeMethod
Renal function test6 months, 12 months, 18 months, 24 months, 30 months, 36 months, 42 months, 48 months, 54 months and 60 months

serum creatinine (mg/dL)

Secondary Outcome Measures
NameTimeMethod
Renal structure6 months, 12 months, 18 months, 24 months, 30 months, 36 months, 42 months, 48 months, 54 months and 60 months

Renal echo (e.g. no hydronephrosis, mild hydronephrosis, moderate hydronephrosis, orsevere hydronephrosis)

Complications6 months, 12 months, 18 months, 24 months, 30 months, 36 months, 42 months, 48 months, 54 months and 60 months

device associated complications (e.g. urinary tract infection, stone formation, hematuria, stent migration)

Trial Locations

Locations (1)

En Chu Kong Hospital

🇨🇳

New Taipei City, Taiwan

© Copyright 2025. All Rights Reserved by MedPath